alexa NRAS mutation status is an independent prognostic factor in metastatic melanoma.
Agri and Aquaculture

Agri and Aquaculture

Journal of Marine Science: Research & Development

Author(s): Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW,

Abstract Share this page

Abstract BACKGROUND: There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) mutations in patients with metastatic melanoma. METHODS: Clinical and pathologic data were collected retrospectively on melanoma patients who were clinically tested for BRAF (exon 15) and NRAS (exons 1 and 2) mutations at The University of Texas M. D. Anderson Cancer Center. Analyses were performed to identify significant associations of mutations with tumor and patient characteristics and with survival from the diagnosis of stage IV disease. RESULTS: The genotypes of the full cohort (n = 677) were 47\% BRAF mutation, 20\% NRAS mutation, and 32\% wild-type for BRAF and NRAS ("WT"). Tumor mutation status was associated (P = .008) with the risk of central nervous system involvement at the diagnosis of stage IV disease, with a higher prevalence observed in BRAF-mutant (24\%) and NRAS-mutant (23\%) patients than in WT patients (12\%). Among patients with nonuveal melanoma who underwent mutation testing within 6 months of stage IV diagnosis (n = 313), patients with NRAS mutations had a median survival of 8.2 months from stage IV diagnosis, which was shorter than the median survival of WT patients (15.1 months; P = .004). Multivariate analysis of this population incorporating age, sex, metastases (M1) category, serum lactate dehydrogenase level, and mutation status confirmed that NRAS mutations are associated independently with decreased overall survival (vs WT; P = .005; hazard ratio, 2.05). CONCLUSIONS: Patients with BRAF or NRAS mutations were more likely than WT patients to have central nervous system involvement at the time they were diagnosed with distant metastatic disease. NRAS mutation status was identified as an independent predictor of shorter survival after a diagnosis of stage IV melanoma. Copyright © 2011 American Cancer Society.
This article was published in Cancer and referenced in Journal of Marine Science: Research & Development

Relevant Expert PPTs

Relevant Speaker PPTs

  • Kun Yin
    Make Your Immunology Research Easy
    PPT Version | PDF Version
  • Anjana Rajput
    Conservation of superior phenotypes of teak (Tectona grandis) in central India
    PPT Version | PDF Version
  • Soha S M Mostafa
    Phycoremediation of olive mill wastewater (OMW) using cyanobacteria for sustainable bio fertilizer and biofuel production
    PPT Version | PDF Version
  • M V Raghavendra Rao
    Medical research – Scorpion as model
    PPT Version | PDF Version
  • A K Sreekala
    Floral structure in relation to pollination and breeding system of selected endemic Impatiens of Western Ghats
    PPT Version | PDF Version
  • Manche Santoshi Kumari
    Prevalence of otological disorders in diabetic patients with hearing loss
    PPT Version | PDF Version
  • Lavanya Rayapu
    PPT Version | PDF Version
  • Chol-Bum ‘Mike’ Kweon
    PPT Version | PDF Version
  • S. R. Gollahalli
    PPT Version | PDF Version
  • Saroj Velamakanni
    Multiparameter analysis using cell cycle biomarkers for breast cancer: Prognostic and predictive implications
    PPT Version | PDF Version
  • Hazel Gorham
    Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
    PPT Version | PDF Version
  • Wang Bin
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Lu Jia
    PPT Version | PDF Version
  • Ola A Mohamed
    E-BABE-Recycling leather wastes in carton industry
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version